Two Stories, One Dilemma
A 52-year-old non-smoking accountant books a comprehensive health scan. He feels well, has no symptoms, and attends mostly because a colleague recommended it. The CT scan shows a small lung nodule. It’s biopsied and turns out to be an early cancer. Surgery removes it completely. He returns to work a month later. His prognosis is excellent. He had no warning signs; without the scan, this cancer might only have appeared at a later, less curable stage.
A 45-year-old teacher also feels well. Her scan shows a “suspicious” kidney mass. She is told it might be a small cancer. She has repeat imaging, then a biopsy. The biopsy bleeds, and she has to be hospitalised overnight. The pathology comes back as a benign lipoma, a harmless growth. The process takes weeks and costs far more than the original scan. She worries for months and is now anxious about future tests. Nothing needed treatment, but the cascade of follow-up caused her real harm.
These stories illustrate a dilemma: some individuals benefit greatly from comprehensive screening; others are exposed to tests, costs, and anxiety, with little or no gain.
Rise of Full Body Screening Clinics
A new centre in Cape Town’s Waterfront is part of a global trend to offer high-tech health assessments to people who feel well: a head-to-toe review using CT scans, mammography, blood tests, body-composition analysis, vision and hearing checks, and stool tests. The package is sold as early detection for cancer, heart disease, diabetes, thyroid, liver and kidney disease, COPD, osteoporosis, and more. A doctor consults with clients at the end and gives recommendations.
This is part of a growing market in which people buy comprehensive screening for themselves outside the usual healthcare system. Such services are spreading across Asia, the Middle East and now Africa. They promise peace of mind and the chance to catch serious disease early, which is especially appealing in places where routine screening isn’t widely accessible.
Japanese Origin Story
This style of comprehensive check-up has roots in Japan’s “Ningen Dock”, a comprehensive and thorough health check-up system offered by many Japanese companies. The name is a metaphor for “ships docking for inspection and repair,” and the program uses a wide array of tests, including physical exams, blood and urine tests, and imaging like X-rays and ultrasounds, to provide a detailed snapshot of an individual’s health.
The goals of Ningen Dock are to catch serious diseases like cancer in their early stages, identify lifestyle-related illnesses, and promote overall wellness. This practice emerged in the context of high population health literacy, strong employer-based healthcare systems, and a cultural emphasis on prevention and routine check-ups.
Japan has one of the highest life expectancies in the world, about 85 years, but Ningen Dock is not the only driver of longevity; other factors such as diet, social cohesion, vaccination, strong primary care, low smoking rates, and universal access to care play important roles.
A Note from the Edo Museum
Health culture starts early. From a 2019 visit to the Edo Museum in Tokyo, this is a curated display of Japanese school lunches from 1960 onward. Japanese life expectancy is influenced not only by screening but by decades of healthier childhood nutrition.
In Japan, some check-ups include CT or MRI, but mostly they rely on more modest tests such as ultrasound, ECGs, endoscopy (for stomach cancer), and basic blood work. Still, the private market has pushed toward more detailed imaging and testing, and this version has now been exported internationally.
Does Comprehensive Screening work? What the Evidence Says
How well does the model translate outside Japan, and what does the evidence say?
Most public-health authorities don’t recommend whole-body screening for people without symptoms. This includes the US Preventive Services Task Force, UK’s NICE and National Screen Committee, European screening authorities, and most national cancer agencies.
Here are the main reasons why.
1. No clear mortality benefit
Whole-body CT and broad cancer panels have not been shown to reduce deaths from cancer or heart disease in low-risk adults who are without symptoms.
2. Overdiagnosis
These tests often detect abnormalities that would never cause illness.
3. False positives and cascades of tests and procedures
A single borderline finding can trigger additional scans, biopsies, scopes, or surgery. These follow-ons create risk and cost without clear benefit.
4. Radiation exposure
Even low-dose CT adds to cumulative lifetime radiation. If repeated every year, the risk becomes meaningful and may increase future cancer risk.
5. Weak evidence for many cancer screens
Screening for pancreatic, ovarian, kidney, and some other cancers is not recommended in the general population because the tests are inaccurate or do not reduce mortality.
6. Statistical noise
Large test panels throw up ‘abnormal’ results by chance.
7. Poor cost-effectiveness
Broad screening absorbs resources and generates high downstream costs. Public health systems are required to prioritise interventions with proven population benefit.
8. False reassurance
A normal scan does not rule out future disease. People may ignore symptoms later because they “passed” a comprehensive check.
9. Psychological harm
Unexpected findings, even benign ones, can create long-term anxiety. Many people struggle to “unhear” the word “nodule.”
10. Equity concerns
These clinics serve mainly higher-income users. They can pull staff and equipment capacity away from those with symptoms or high-risk conditions.
Public-health agencies have to weigh up population impact rather than individual anecdotes. Their bottom line is that for most people without symptoms, the balance of benefit and harm is unfavourable.
Screening That Does Work
The idea of a detailed health scan is intuitively appealing. Many people know someone whose deadly cancer was found by chance and treated successfully. Stories of “saved lives” circulate widely and are real. But so are the stories of unnecessary biopsies, complications, costs and sleepless nights.
The challenge with full-body screening is that we can’t reliably tell in advance who will be helped and who will be harmed.
By contrast, a small number of screening tests have clear evidence of population benefit:
- Cervical cancer
- Breast cancer (certain age groups)
- Colorectal cancer
- Lung cancer (in heavy smokers)
- Hypertension (high blood pressure)
- Diabetes (in high-risk groups)
- Hepatitis-linked liver cancer (in cirrhosis)
These are backed by randomised trials and cost-effectiveness analysis. Broad screening beyond these areas is unproven.
Precision Testing and the Future
The growth of high-tech screening centres also reflects a shift toward personal choice, where individuals buy information that may or may not change their health trajectory.
Screening decisions will become more complex in coming years. An ever wider range of “precision medicine” tests is moving from research labs into practice – new genetic and blood-based tests, including multi-cancer early detection tools like the Galleri test GRAIL (around $1000). These tests may eventually prove useful, but no multi-cancer blood test has yet shown a reduction in cancer deaths.
These tools are most likely to help people with known higher underlying risk, such as lifelong smokers, or a strong family history, where the balance of benefit and harm shifts in favour of screening. The challenge is to understand when that threshold is reached: the level of individual or population risk, the cost of testing, and the expected downstream consequences. Some individuals or groups will meet that threshold, and for them these approaches make practical sense.
Bottom Line
For now, we should watch this space closely, as evidence and technology evolve.
As the model expands in Africa and elsewhere, it’s important to understand both the promise and the pitfalls. Screening is not inherently good or bad, it’s a trade-off which differs by age, risk profile, personal values, and local healthcare context.
Some people will gain from an early diagnosis. Others will enter a cascade of follow-ups they did not anticipate.
Understand this before you sign up.